These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 38725029)

  • 1. Reduced cerebrospinal fluid motion in patients with Parkinson's disease revealed by magnetic resonance imaging with low b-value diffusion weighted imaging.
    Pierobon Mays G; Hett K; Eisma J; McKnight CD; Elenberger J; Song AK; Considine C; Richerson WT; Han C; Stark A; Claassen DO; Donahue MJ
    Fluids Barriers CNS; 2024 May; 21(1):40. PubMed ID: 38725029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced suprasellar cistern cerebrospinal fluid motion in patients with Parkinson's disease revealed by magnetic resonance imaging with dynamic cycling of diffusion weightings.
    Mays GP; Hett K; Eisma J; McKnight CD; Elenberger J; Song AK; Considine C; Han C; Stark A; Claassen DO; Donahue MJ
    Res Sq; 2023 Sep; ():. PubMed ID: 37720044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diffusion analysis of fluid dynamics with incremental strength of motion proving gradient (DANDYISM) to evaluate cerebrospinal fluid dynamics.
    Taoka T; Kawai H; Nakane T; Abe T; Nakamichi R; Ito R; Sato Y; Sakai M; Naganawa S
    Jpn J Radiol; 2021 Apr; 39(4):315-323. PubMed ID: 33389526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced α-synuclein levels in cerebrospinal fluid in Parkinson's disease are unrelated to clinical and imaging measures of disease severity.
    van Dijk KD; Bidinosti M; Weiss A; Raijmakers P; Berendse HW; van de Berg WD
    Eur J Neurol; 2014 Mar; 21(3):388-94. PubMed ID: 23631635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease.
    Hong Z; Shi M; Chung KA; Quinn JF; Peskind ER; Galasko D; Jankovic J; Zabetian CP; Leverenz JB; Baird G; Montine TJ; Hancock AM; Hwang H; Pan C; Bradner J; Kang UJ; Jensen PH; Zhang J
    Brain; 2010 Mar; 133(Pt 3):713-26. PubMed ID: 20157014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
    Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
    Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraventricular cerebrospinal fluid temperature analysis using MR diffusion-weighted imaging thermometry in Parkinson's disease patients, multiple system atrophy patients, and healthy subjects.
    Sumida K; Sato N; Ota M; Sakai K; Nippashi Y; Sone D; Yokoyama K; Ito K; Maikusa N; Imabayashi E; Matsuda H; Yamada K; Murata M; Kunimatsu A; Ohtomo K
    Brain Behav; 2015 Jun; 5(6):e00340. PubMed ID: 26085965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Connectome analysis with diffusion MRI in idiopathic Parkinson's disease: Evaluation using multi-shell, multi-tissue, constrained spherical deconvolution.
    Kamagata K; Zalesky A; Hatano T; Di Biase MA; El Samad O; Saiki S; Shimoji K; Kumamaru KK; Kamiya K; Hori M; Hattori N; Aoki S; Pantelis C
    Neuroimage Clin; 2018; 17():518-529. PubMed ID: 29201640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MRI-visible perivascular spaces are associated with cerebrospinal fluid biomarkers in Parkinson's disease.
    Fang Y; Gu LY; Tian J; Dai SB; Chen Y; Zheng R; Si XL; Jin CY; Song Z; Yan YP; Yin XZ; Pu JL; Zhang BR
    Aging (Albany NY); 2020 Nov; 12(24):25805-25818. PubMed ID: 33234732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decoupling of Global Brain Activity and Cerebrospinal Fluid Flow in Parkinson's Disease Cognitive Decline.
    Han F; Brown GL; Zhu Y; Belkin-Rosen AE; Lewis MM; Du G; Gu Y; Eslinger PJ; Mailman RB; Huang X; Liu X
    Mov Disord; 2021 Sep; 36(9):2066-2076. PubMed ID: 33998068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A rapid α-synuclein seed assay of Parkinson's disease CSF panel shows high diagnostic accuracy.
    Orrù CD; Ma TC; Hughson AG; Groveman BR; Srivastava A; Galasko D; Angers R; Downey P; Crawford K; Hutten SJ; Kang UJ; Caughey B
    Ann Clin Transl Neurol; 2021 Feb; 8(2):374-384. PubMed ID: 33373501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of α-synuclein aggregate formation by CSF exosomes from patients with Parkinson's disease and dementia with Lewy bodies.
    Stuendl A; Kunadt M; Kruse N; Bartels C; Moebius W; Danzer KM; Mollenhauer B; Schneider A
    Brain; 2016 Feb; 139(Pt 2):481-94. PubMed ID: 26647156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between cerebrospinal fluid biomarkers and structural brain network properties in Parkinson's disease.
    Abbasi N; Mohajer B; Abbasi S; Hasanabadi P; Abdolalizadeh A; Rajimehr R
    Mov Disord; 2018 Mar; 33(3):431-439. PubMed ID: 29436735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Choroid plexus perfusion and intracranial cerebrospinal fluid changes after angiogenesis.
    Johnson SE; McKnight CD; Lants SK; Juttukonda MR; Fusco M; Chitale R; Donahue PC; Claassen DO; Donahue MJ
    J Cereb Blood Flow Metab; 2020 Aug; 40(8):1658-1671. PubMed ID: 31500523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlates of cerebrospinal fluid levels of oligomeric- and total-α-synuclein in premotor, motor and dementia stages of Parkinson's disease.
    Compta Y; Valente T; Saura J; Segura B; Iranzo Á; Serradell M; Junqué C; Tolosa E; Valldeoriola F; Muñoz E; Santamaria J; Cámara A; Fernández M; Fortea J; Buongiorno M; Molinuevo JL; Bargalló N; Martí MJ
    J Neurol; 2015 Feb; 262(2):294-306. PubMed ID: 25380583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Choroid plexus volume is associated with levels of CSF proteins: relevance for Alzheimer's and Parkinson's disease.
    Tadayon E; Pascual-Leone A; Press D; Santarnecchi E;
    Neurobiol Aging; 2020 May; 89():108-117. PubMed ID: 32107064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing pulsatile waveforms of paravascular cerebrospinal fluid dynamics within the glymphatic pathways using dynamic diffusion-weighted imaging (dDWI).
    Wen Q; Tong Y; Zhou X; Dzemidzic M; Ho CY; Wu YC
    Neuroimage; 2022 Oct; 260():119464. PubMed ID: 35835339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can low b value diffusion weighted imaging evaluate the character of cerebrospinal fluid dynamics?
    Taoka T; Naganawa S; Kawai H; Nakane T; Murata K
    Jpn J Radiol; 2019 Feb; 37(2):135-144. PubMed ID: 30406868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal fluid levels of alpha-synuclein, amyloid β, tau, phosphorylated tau, and neuron-specific enolase in patients with Parkinson's disease, dementia with Lewy bodies or other neurological disorders: Their relationships with cognition and nuclear medicine imaging findings.
    Katayama T; Sawada J; Kikuchi-Takeguchi S; Kano K; Takahashi K; Saito T; Okizaki A; Hasebe N
    Neurosci Lett; 2020 Jan; 715():134564. PubMed ID: 31733322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does cerebrospinal fluid pulsation affect diffusion-weighted imaging thermometry? A study in healthy volunteers.
    Sakai K; Kentaro A; Tazoe J; Ikeno H; Nakagawa T; Yamada K
    NMR Biomed; 2022 Aug; 35(8):e4738. PubMed ID: 35388508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.